Leqembi is currently approved for the treatment of early Alzheimer disease and is administered by IV infusion once every 2 weeks. Findings showed that treatment with the weekly SC formulation resulted ...
For the Endo IV family and the functionally related APE1 family of AP endonucleases 27, an understanding of both the catalytic mechanism and how the chemistry avoids release of toxic cleaved DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback